The percentage cured (95% confidence intervals) was reported to be:
intramuscular ceftriaxone 125mg for single urogenital or rectal site (SS), 98.7 - 99.8;
intramuscular ceftriaxone 125mg for pharynx, 84.5 - 98.2;
intramuscular ceftriaxone 125mg for multiple or unspecified sites, 86.8 - 100.
The rates for the remaining drugs considered in the study, according to the type of site were as follows:
cefixime 400mg, 96.1 - 99.3 (SS), 63.1 - 100 (PH), 75.3 - 100 (MU);
ofloxacin 400mg, 97.3 - 99.3 (SS), 68.8 - 97.5 (PH), 68.8 - 97.5(MU);
ciprofloxacin 500mg, 95.9 - 100 (SS), 68 - 99.8 (PH);
azithromycin 1g, 91.4 - 98.9 (SS), 82.3 - 100 (PH), and 93.7 - 99.5 (MU).
The values adopted for the clinical probabilities were as follows:
proportion of infected women seeking medical care for symptomatic cervicitis were 20% to 80%;
proportion seeking care for acute pelvic inflammatory disease (PID), 10 to 23%;
proportion of hospitalised patients with PID, 12 to 25%;
infertility rate in patients with PID, 10 to 20%;
ectopic pregnancy rate in patients with PID, 4 to 6%;
proportion of patients with PID experiencing chronic pelvic pain, 17 to 18%;
birth rate for infected women, 3 to 6%;
percentage of neonates borne by mothers with gonorrhoea developing ophthalmia neonatorum, 2 to 30%;
proportion of infected men seeking medical care for symptomatic urethritis, 50 to 90%.